<DOC>
	<DOCNO>NCT00188565</DOCNO>
	<brief_summary>Colorectal carcinoma third common cause death cancer . Approximately , 30 % colorectal carcinoma involve rectum . Optimizing local control pelvis reduce treatment toxicity remain one principal goal therapy patient locally advanced rectal carcinoma . Treatment strategy achieve goal significant impact society.C linical trial show type cancer less likely come back chemotherapy radiotherapy add surgery . A combination three type therapy standard . Celecoxib ( CelebrexÂ® ) drug lessen action enzyme call cyclooxygenase-2 ( COX-2 ) also know `` COX-2 inhibitor '' . It anti-inflammatory capsule ( drug reduces irritation ) commonly use treat arthritis . It chemotherapy drug . Laboratory experiment show COX-2 inhibitor may increase anti-cancer effect radiotherapy , without increase radiation side effect . This yet confirm humans.The main purpose study confirm celecoxib increase side effect give radiotherapy chemotherapy rectal cancer . We shall also look effective combination radiotherapy , chemotherapy celecoxib shrink rectal cancer .</brief_summary>
	<brief_title>Celebrex With Preoperative Chemoradiation - Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>patient resectable potentially resectable adenocarcinoma rectum clinical stage T2 N12 T34 N02 ( patient require divert loop colostomy eligible ) age great 18 year , ECOG performance status &lt; 2 ( appendix , section 13.1 ) biopsy proven adenocarcinoma , superior margin tumour within 15cm anal verge rigid sigmoidoscopy Distant metastasis , Prior pelvic irradiation , Inflammatory bowel disease , Medical condition preclude radical therapy History malignancy within five year ( except nonmelanoma skin cancer , CIN cervix ) Pregnancy Hypersensitivity celecoxib , NSAID , sulfonamides 5FU Significant comorbid illness History peptic ulcer disease NSAIDrelated gastrointestinal bleeding Use aspirin , NSAID coxib two week prior study entry Neutrophil count &lt; 1.5x109/L , platelet count &lt; 100x109/L , serum bilirubin &gt; 1.25xULN ( upper limit normal ) , AST/ALT &gt; 3xULN , serum creatinine &gt; 1.25xULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>